Narrow search
Showing 1 - 10 of 45,611
Cover Image
The distribution of surplus in the US pharmaceutical industry : evidence from paragraph iv patent-litigation decisions
Jacobo-Rubio, Ruben; Turner, John L.; Williams, Jonathan W. - In: The journal of law & economics 63 (2020) 2, pp. 203-238
Persistent link: https://www.econbiz.de/10012513603
Cover Image
Generic drug approval
Brockhoff, Klaus - In: Intellectual property rights and global competition : …, (pp. 215-230). 1995
Persistent link: https://www.econbiz.de/10001290374
Cover Image
Implementing personalized medicine with asymmetric information on prevalence rates
Antoñanzas Villar, Fernando; Juárez-Castelló, Carmelo A. - In: Health economics review 6 (2016) 35, pp. 1-8
Although personalized medicine is becoming the new paradigm to manage some diseases, the economics of personalized medicine have only focused on assessing the efficiency of specific treatments, lacking a theoretical framework analyzing the interactions between pharmaceutical firms and healthcare...
Persistent link: https://www.econbiz.de/10011586604
Cover Image
Pharmaceutical Generics, Vertical Product Differentiation, and Public Policy
Cabrales, Antonio - 2003
This paper studies oligopolistic competition in off-patent pharmaceutical markets using a vertical product … prices by patent owners after entry of generic producers. differentiation …
Persistent link: https://www.econbiz.de/10014086792
Cover Image
Optimal patent policy for pharmaceutical industry
Izhak, Olena; Saxell, Tanja; Takalo, Tuomas - 2020
Persistent link: https://www.econbiz.de/10012439514
Cover Image
Generic drug shortages and undifferentiated competition
Choi, Seung-chan - In: Advances in National Brand and Private Label Marketing …, (pp. 53-59). 2024
Persistent link: https://www.econbiz.de/10015077056
Cover Image
Optimal Patent Policy for Pharmaceutical Industry
Izhak, Olena; Saxell, Tanja; Takalo, Tuomas - 2020
We show how characterizing optimal patent policy for the pharmaceutical industry only requires information about …, we use data on Paragraph IV patent challenges, and two quasi-experimental approaches: one based on changes in patent laws … and another on the allocation of patent applications to examiners. We find that extending effective patent duration …
Persistent link: https://www.econbiz.de/10014097057
Cover Image
Economic analysis of pay-for-delay settlements and their legal ruling
Gratz, Linda - 2012
In this paper, we ask whether courts should continue to rule settlements in the context of pharmaceutical claims per se legal, when these settlements comprise payments from originator to generic companies, potentially delaying generic entry compared to the underlying litigation. Within a...
Persistent link: https://www.econbiz.de/10009490191
Cover Image
Regulating Innovation : Competition Policy and Patent Law under Uncertainty
Manne, Geoffrey A.; Wright, Joshua D. - 2013
This essay is the introduction to a forthcoming volume entitled, Regulating Innovation: Competition Policy and Patent … relationship between regulation - both through competition policy and patent law - and innovation, and the corresponding …
Persistent link: https://www.econbiz.de/10014046279
Cover Image
A Short-Run Welfare Analysis of the Hatch-Waxman Act, with and Without Ftc Antitrust Regulation of Patent Litigation Settlements
Ecer, Sencer - 2014
We compare the short-run welfare effects of two types of settlement agreements, quot;reverse paymentsquot; of the brand-name drug makers to generic producers not to enter the market and delayed entry when these payments are restricted both under the entry injunction (imposed by the Hatch-Waxman...
Persistent link: https://www.econbiz.de/10012752136